ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.

California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent committee ruled that it was unlikely to meet its ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

BeiGene to discontinue its ociperlimab lung cancer trial after a futility analysis showed it was unlikely to meet overall survival endpoint. AdvanTIG-302 trial compared ociperlimab+tislelizumab to ...

Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...

BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

"At BeiGene, we are committed to expanding access to innovative and affordable cancer treatments for more patients around the world. This partnership with Ebn Sina Medical reflects our shared goal ...